217 related articles for article (PubMed ID: 19365180)
1. Hypercalcemia associated with tertiary hyperparathyroidism managed conservatively with pamidronate in a hemodialysis patient.
Czosnowski LM; Hudson JQ; Canada RB
Am J Med Sci; 2009 Apr; 337(4):300-1. PubMed ID: 19365180
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
4. Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism.
Tal A; Graves L
South Med J; 1996 Jun; 89(6):637-40. PubMed ID: 8638211
[TBL] [Abstract][Full Text] [Related]
5. Parathyromatosis and the challenge of treatment.
Daphnis E; Stylianou K; Katsipi I; Stratigis S; Karamitopoulou E; Karkavitsas N; Kyriazis J
Am J Kidney Dis; 2006 Sep; 48(3):502-5. PubMed ID: 16931226
[TBL] [Abstract][Full Text] [Related]
6. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient.
Trimarchi H; Lombi F; Forrester M; Elizondo C; Sawinski D; Pereyra H; Freixas E
Nat Clin Pract Nephrol; 2006 Aug; 2(8):459-63; quiz 464. PubMed ID: 16932480
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure.
Davenport A; Goel S; Mackenzie JC
Scand J Urol Nephrol; 1993; 27(4):447-51. PubMed ID: 8159916
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the treatment of bisphosphonate resistant hypercalcemia in a hemodialysis patient.
Dahmani O; Sophoclis C; Kebir M; Bouguern D; Sakho A; Demarchi P
Saudi J Kidney Dis Transpl; 2017; 28(1):154-157. PubMed ID: 28098117
[TBL] [Abstract][Full Text] [Related]
9. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Jansson S; Morgan E
World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
[TBL] [Abstract][Full Text] [Related]
10. The use of pamidronate in three children with renal disease.
Sellers E; Sharma A; Rodd C
Pediatr Nephrol; 1998 Nov; 12(9):778-81. PubMed ID: 9874327
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of pamidronate in severe secondary hyperparathyroidism in patients undergoing hemodialysis.
Torregrosa JV; Moreno A; Mas M; Ybarra J; Fuster D
Kidney Int Suppl; 2003 Jun; (85):S88-90. PubMed ID: 12753274
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of intravenous bisphosphonates in the treatment of primary hyperparathyroidism complicated by hypercalcemia crisis].
Han GY; Wang O; Xing XP; Meng XW; Lian XL; Guan H; Ye W; Xia WB; Li M; Jiang Y; Hu YY; Liu HC; Cui QC
Zhonghua Nei Ke Za Zhi; 2009 Sep; 48(9):729-33. PubMed ID: 20079207
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy with pamidronate and calcitonin in hypercalcemic crisis caused by primary hyperparathyroidism].
Christensen JH; Kristiansen JH
Ugeskr Laeger; 1992 Nov; 154(47):3341-2. PubMed ID: 1462441
[TBL] [Abstract][Full Text] [Related]
14. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
[TBL] [Abstract][Full Text] [Related]
15. A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism.
Ammann P; Herter-Clavel C; Lubrano A; Rizzoli R
Aging Clin Exp Res; 2003 Dec; 15(6):500-4. PubMed ID: 14959954
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
[TBL] [Abstract][Full Text] [Related]
17. Aminohydroxypropylidene diphosphonate treatment of hypercalcemic crisis due to primary hyperparathyroidism.
Evans RA
Aust N Z J Med; 1987 Feb; 17(1):58-9. PubMed ID: 3476049
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate use in two cases of hypercalcaemia secondary to hyperparathyroidism.
Weatherall M
N Z Med J; 1992 Sep; 105(942):389. PubMed ID: 1436854
[No Abstract] [Full Text] [Related]
19. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
Bone; 1990; 11(1):15-20. PubMed ID: 2331426
[TBL] [Abstract][Full Text] [Related]
20. Effects of pamidronate and calcitriol on the set point of the parathyroid gland in postmenopausal hemodialysis patients with secondary hyperparathyroidism.
Huang CY; Zheng CM; Wu CC; Lo L; Lu KC; Chu P
Nephron Clin Pract; 2012; 122(3-4):93-101. PubMed ID: 23635416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]